公开(公告)号：US20230190724A1

公开(公告)日：2023-06-22

申请号：US18172927

申请日：2023-02-22

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61K45/06 ,  A61P25/28

CPC classification number: A61K31/451 ,  A61K45/06 ,  A61P25/28

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.

公开(公告)号：US20230165849A2

公开(公告)日：2023-06-01

申请号：US16952123

申请日：2020-11-19

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61P25/14 ,  A61K9/00

CPC classification number: A61K31/451 ,  A61P25/14 ,  A61K9/0053 ,  A61K9/0019

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US11406625B2

公开(公告)日：2022-08-09

申请号：US16789564

申请日：2020-02-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Ralph Laufer ,  Michael Hayden ,  Neta Zach

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/00 ,  A61K31/185 ,  A61K31/222 ,  A61K31/4152 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/49

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

公开(公告)号：US20220193059A1

公开(公告)日：2022-06-23

申请号：US17425951

申请日：2020-02-04

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA ,  Angela CENCI NILSSON

IPC: A61K31/451 ,  A61P25/16

Abstract: The subject invention provides a method for treating Parkinsonism or symptoms thereof by low dose pridopidine.

公开(公告)号：US20210275512A1

公开(公告)日：2021-09-09

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61P25/14 ,  A61K45/06 ,  A61P25/16 ,  A61K9/00

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia

公开(公告)号：US20200030308A1

公开(公告)日：2020-01-30

申请号：US16535107

申请日：2019-08-08

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Malle SCHMIDT ,  Malle PARI ,  Marit LAOS ,  Ants MAASALU ,  Kalle KALJUSTE

IPC: A61K31/451 ,  C07D211/52 ,  C07D211/24 ,  C07D211/42 ,  G01N30/88

Abstract: This invention provides an isolated compound having the structure: or, or a salt thereof.The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine.This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof. This invention further provides a process for producing a pridopidine drug product comprising obtaining a pridopidine drug substance and mixing the pridopidine drug substance with suitable excipients so as to produce the pridopidine drug product. This invention also provides a process for producing a pridopidine drug product. This invention also provides a process of distributing a pridopidine drug product.

公开(公告)号：US20190336488A1

公开(公告)日：2019-11-07

申请号：US16514167

申请日：2019-07-17

Applicant: PRILENIA NEUROTHERAPEUTICS LTD. ,  NATIONAL UNIVERSITY OF SINGAPORE ,  AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Michael HAYDEN ,  Mahmoud Abdulhossein POULADI

IPC: A61K31/451 ,  A61K9/00 ,  A61P43/00

Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

公开(公告)号：US12036213B2

公开(公告)日：2024-07-16

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61K9/00 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

CPC classification number: A61K31/451 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.

公开(公告)号：US20230112948A1

公开(公告)日：2023-04-13

申请号：US17967415

申请日：2022-10-17

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P25/00 ,  A61P25/24 ,  A61P25/22

Abstract: This invention provides a method of treating depression or anxiety in a human subject by administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230100072A1

公开(公告)日：2023-03-30

申请号：US17980590

申请日：2022-11-04

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P31/14

Abstract: The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.